**Supplemental Table 1.**

**Characteristics of ThAlb and norepinephrine treatments in the 2 groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **ThAlb and norepinephrine treatments** | | | |
|  | **4%-ThAlb** | **20%-ThAlb** | ***p* value** |
| NE infusion length of time (h) | 72 [41·25-215] | 80 [35·5-128] | 0·62 |
| Time 1st albumin to peak of NE infusion (h) | 1 [0-21·5] | 0 [0-5] | 0·08 |
| Time 1st albumin to peak of NE infusion -30% (h) | 18 [5-29] | 8 [0-19] | 0·25 |
| Volume of therapeutic albumin (mL/patient) | 4500 [2500-6375] | 1250 [775-1900] | < 0·001 |
| Weight of therapeutic albumin (g/patient) | 180 [100-255] | 250 [155-380] | 0·06 |
| Albumin-infusion length of time (h) | 83 [35·75-136·5] | 78 [40-137·8] | 0·94 |

*N*: number of patients; NE, Norepinephrine; data are medians [quartile 1; quartile 3]; *p* value is calculated between median values with the Mann-Whitney test according to the two arms of ThAlb (4% *versus* 20%).